Extended half-life recombinant factor VIII treatment of hemophilia A in Brazil: an expert consensus statement

Autor: Margareth Castro Ozelo, Sandra Vallin Antunes, Paula Ribeiro Villaca, Luciana Correa Oliveira, Ieda Solange Pinto, Claúdia Santos Lorenzato, Alessandra Nunes Loureiro Prezotti, Renato Mantelli Picoli

Publikováno v: Hematology, transfusion and cell therapy.

Treatment of hemophilia A in Brazil is offered to all patients at no cost. However, several unmet medical needs exist.In this study, we applied the Delphi method to discuss with seven hemophilia A specialists the challenges that patients and the heal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ad515326f871daf04fe929541f93866
https://pubmed.ncbi.nlm.nih.gov/36604239

Immune status of patients with haemophilia A before exposure to factor VIII: first results from the HEMFIL study

Autor: M. Cerqueira, Johanna G. van der Bom, Letícia Lemos Jardim, Vivian Karla Brognoli Franco, Daniel G. Chaves, Claudia Santos Lorenzato, Suely M. Rezende, Alessandra Nunes Loureiro Prezotti, Ana Cristina Simões e Silva, Amanda C. O. Silveira-Cassette, Marcio P. Santana

Publikováno v: British Journal of Haematology, 178(6), 971-978

Summary Previous cross-sectional studies showed that some patients with haemophilia A (HA) without inhibitor presented a pro-inflammatory profile during factor VIII (FVIII) replacement therapy. Furthermore, an anti-inflammatory/regulatory state was d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5359886cf5acb23738f13ddf6f4a32dc
https://hdl.handle.net/1887/115542

A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A

Autor: Kaan Kavakli, Mamta Manglani, Ezio Zanon, Christoph Male, Tarek Owaidah, Johnny Mahlangu, Ramabadran Varadarajan, Veronica Soto Arellano, Flora Peyvandi, Alessandra Nunes Loureiro Prezotti, Monica Martinez, Frits R. Rosendaal, Cecil Ross, Suresh Hanagavadi, Suvankar Majumdar, Bulent Zulfikar, Anupam Sachdeva, Brian M. Wicklund, Amal El-Beshlawy, Marilyn J. Manco-Johnson, M. Cerqueira, Dinesh M Nayak, Pier Mannuccio Mannucci, Santiago Bonanad Boix, Nadia P. Ewing, Klaus Schmitt, Angeles Palomo Bravo, Nathan L Kobrinsky, Maria Elisa Mancuso, Shashikant Apte, Mathew Thomas, Isabella Garagiola, Rogelio Paredes Aguilera, Guy Young, Maria Gabriella Mazzucconi, Esperanza Marzouka, Rosario Perez Garrido, Tulika Seth, Bülent Antmen, Mohsen Saleh Elalfy, Peyman Eshghi, E. Santagostino, Mindy L. Simpson, Vijay Ramanan, Daniela Neme, Mehran Karimi, Adriana C Sandoval Gonzalez

Publikováno v: New England Journal of Medicine, 374(21), 2054-2064
NEW ENGLAND JOURNAL OF MEDICINE
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

WOS: 000376443500008
PubMed ID: 27223147
BACKGROUND The development of neutralizing anti-factor VIII alloantibodies (inhibitors) in patients with severe hemophilia A may depend on the concentrate used for replacement therapy. METHODS We con

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea0706f075d71f088bb7ee2416552359
http://hdl.handle.net/1887/113139

Incidence of Inhibitors in a Previously Untreated Patients with Severe Hemophilia Α Cohort Treated with a Single Third-Generation Recombinant Factor VIII Concentrate

Autor: Rosangela Ribeiro, Alessandra Nunes Loureiro Prezotti, Maria P S V Orletti, Paula Ribeiro Villaça, Gabriela G Yamaguti-Hayakawa, Ieda S. Pinto, Maria do Rosário Ferraz Roberti, Margareth C. Ozelo, Clarissa Ferreira, Carolina Costa-Lima, Marília Sande Renni, M. Cerqueira, Samuel de Souza Medina

Publikováno v: Blood. 132:1211-1211

Introduction: One of the most important complications in the treatment of patients with hemophilia A is the formation of neutralizing antibodies (inhibitors) interfering in the coagulant activity of factor VIII (FVIII). The presence of inhibitor caus

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::44afe68799a7d5a209a25636750e6029
https://doi.org/10.1182/blood-2018-99-119754

Source of Factor VIII Replacement (PLASMATIC OR RECOMBINANT) and Incidence of Inhibitory Alloantibodies in Previously Untreated Patients with Severe Hemophilia a: The Multicenter Randomized Sippet Study

Autor: Guy Young, Johnny Mahlangu, Monica Martinez, Cecil Ross, Suresh Hanagavadi, M. Cerqueira, Esperanza Marzouka, Rosario Perez Garrido, Alessandra Nunes Loureiro Prezotti, Christoph Male, Schmitt Klaus, Mamta Manglani, Tarek Owaidah, Rosendaal R. Frits, Amal El-Beshlawy, Pier Mannuccio Mannucci, Adriana C. Sandoval Gonzales, Madatha V. Ramanan, Kaan Kavakli, Angeles Palomo Bravo, Maria Gabriella Mazzucconi, Elena Santagostino, Dinesh M Nayak, Nadia P. Ewing, Isabella Garagiola, Maria Elisa Mancuso, Ezio Zanon, Peyman Eshghi, Suvankar Majumdar, Bulent Zulfikar, Flora Peyvandi, Anupam Sachdeva, Marilyn J. Manco-Johnson, Ali Bülent Antmen, Veronica Soto Arellano, Mohsen Saleh Elalfy, Rogelio Paredes Aguilera, Brian M. Wicklund, Tulika Seth, Nathan L. Kobrinsky, Santiago Bonanad, Ramabadran Varadarajan, Daniela Neme, Mathew Thomas, Mehran Karimi, Mindy L. Simpson, Shashikant Apte

Publikováno v: Blood. 126:5-5

Background We conducted an investigator-driven, multicenter, open label, randomized study to establish whether the source of factor VIII (FVIII) replacement (plasma-derived, pd; or recombinant, r) affects the rate of inhibitory alloantibodies in prev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::50b98dbd33b1ede03ce914ad423b700e
https://doi.org/10.1182/blood.v126.23.5.5